Abstract: A computer-implemented method for evaluating and optimizing a large language model (LLM) includes receiving input data for a large language model; transforming the input data into a standardized format compatible with a multi-metric evaluation framework; applying a set of evaluation metrics to the transformed data, wherein the set of metrics comprises a hallucination metric, a groundedness metric, a relevance metric, a recall metric, a precision metric, a consistency metric, and a Coherence metric; generating an error function that quantifies an overall performance of the LLM, wherein the error function takes as input parameters of the LLM and incorporates the set of evaluation metrics to produce an error score; minimizing the error function wherein a lower error score indicates better performance of the LLM; and outputting an improved LLM with improved parameters.

Abstract: Disclosed herein are isolated peptides, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer's. In an example, an isolated polypeptide includes a cyclin dependent kinase 5 (Cdk5) inhibitory domain that has at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, wherein the Cdk5 inhibitory domain is linked to a protein transduction domain. Methods of reducing or inhibiting one or more symptoms associated with a neurodegenerative disease by administering a therapeutically effective amount of a pharmaceutical composition including one or more disclosed peptides are also provided.

Abstract: Disclosed herein are isolated peptides, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer's. In an example, an isolated polypeptide includes a cyclin dependent kinase 5 (Cdk5) inhibitory domain that has at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, wherein the Cdk5 inhibitory domain is linked to a protein transduction domain. Methods of reducing or inhibiting one or more symptoms associated with a neurodegenerative disease by administering a therapeutically effective amount of a pharmaceutical composition including one or more disclosed peptides are also provided.